Zybio successfully developed Molaccu SARS-CoV-2 B.1.1.7 Variant Assay Kit

January 12,2021 Zybio News

In mid-December 2020, the United Kingdom reported to the WHO that a mutant strain of SARS-CoV-2 was discovered, and the infectivity of the virus after the mutation increased by 40 to 70%. At present, Shanghai, Shandong and other places have successively discovered B.1.1.7 variant of SARS-CoV-2 imported cases. The rapid detection of the highly infectious SARS-CoV-2 B.1.1.7 variant has become the key step of epidemic prevention and control.


Based on the latest global epidemic prevention situation, Zybio quickly organized a technical team to respond to the needs of pandemic prevention, and has successfully developed the SARS-CoV-2 B.1.1.7 Variant Assay Kit. The kit selects missense mutation site N501Y and deletion mutation site HV 69-70del related to infectious enhancement in SARS-CoV-2 S gene to detect.

Molaccu SARS-CoV-2 B.1.1.7 Variant Assay Kit can be used with Zybio's Nucleic Acid Extraction Kit and Automatic Nucleic Acid isolation system EXM6000 to achieve the fastest nucleic acid extraction of 96 samples in 12 minutes, and results in 1 hour. Zybio's solution provides support for fight against the current pandemic.

Zybio can provide a whole solution for the variant strain of SARS-CoV-2, complete the diagnosis of a large number of suspected patients in a short period of time; quickly diagnose infected patients and help severely-hit regions to improve the efficiency of virus detection.